The US company will be operating out of its office in Research Triangle Park, North Carolina. In addition, the company has appointed Eric Nelson as its global head of business development, marketing and strategy.
Dr Nelson with over 20 years of corporate and business development experience with both large pharmaceutical and biotechnology companies would be based out of the company’s US office and will have the responsibility of managing its operations. Eric joins Advinus from Tranzyme Pharma where he was vice president of business development and licensing.
Rashmi Barbhaiya, CEO and managing director of Advinus Therapeutics, said: “Advinus has a very large and growing client base in the US. In addition we now have multiple drug discovery alliances and collaborations with both large Pharma and Biotechs based out of the US. One of the main reasons to start the US operations of our company is to build on these relationships and to expand into new ones.”